Skip to main content
SKINBIOTHERAPEUTICS PLC logo

SKINBIOTHERAPEUTICS PLC — Investor Relations & Filings

Ticker · SBTX ISIN · GB00BF33H870 LEI · 213800YMQOCB23FX6I06 IL Manufacturing
Open in API
Filings indexed 315 across all filing types
Latest filing 2023-06-21 Environmental & Social …
Country GB United Kingdom
Listing IL SBTX

About SKINBIOTHERAPEUTICS PLC

https://www.skinbiotherapeutics.com/

SkinBioTherapeutics PLC is a life science company focused on advancing skin health by harnessing the human microbiome. Its proprietary SkinBiotix® platform technology utilizes probiotic lysates to protect, manage, and restore skin. The company develops and commercializes products across several healthcare sectors, including cosmetics, food supplements, medical devices, and pharmaceuticals. Key offerings include AxisBiotix, a probiotic food supplement designed to address psoriasis symptoms, and the Dermatonics line of specialized foot care products. Through its acquisition of Bio-Tech Solutions, the company also provides formulation, manufacturing, and packaging services for healthcare, personal care, and hygiene products.

Recent filings

Filing Released Lang Actions
Regulatory Approval
Environmental & Social Information Classification · 99% confidence The document begins with 'RNS Number : 3593D' and contains standard regulatory boilerplate language, including references to 'RNS, the news service of the London Stock Exchange' and 'Market Abuse Regulation (EU) No. 596/2014'. The content is a brief announcement regarding regulatory approval for a product launch in Italy, with updates on future launches. This format strongly indicates a general regulatory news service announcement rather than a comprehensive financial report (like 10-K or IR) or a specific document type like a proxy statement or earnings release. Since it is a general regulatory announcement distributed via RNS that doesn't fit the more specific categories (like DIV, DIRS, ER, etc.), the most appropriate classification is the general regulatory filing category.
2023-06-21 English
Business progress update
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated June 14, 2023. It provides a 'Business update' covering progress across various company pillars (SkinBiotix™, AxisBiotix-PS™, MediBiotix™) and mentions ongoing acquisition investigations. The text concludes by stating that the information 'communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014' and is distributed by 'RNS, the news service of the London Stock Exchange.' This structure—a brief update disseminated via the RNS system, often containing material non-public information—is characteristic of a general regulatory announcement that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-14 English
SkinBiotix and AxisBiotix Update
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '10 May 2023'. It contains bullet points summarizing business updates regarding partnerships (SkinBiotix™ with Sederma/Croda) and product launches (AxisBiotix™ in Spain). The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and source identification strongly indicate a regulatory news service announcement. Since the content is a general business update that doesn't fit specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Change (CAP), the most appropriate classification is the general regulatory announcement fallback category.
2023-05-10 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification filed via RNS (RNS Number: 1821W) dated April 14, 2023. The content explicitly details transactions involving the sale and purchase of ordinary shares by Persons Discharging Managerially Responsibilities (PDMRs), specifically the CEO and CFO. This directly matches the definition of Director's Dealing (insider trades). The classification code for this is DIRS.
2023-04-14 English
Replacement Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'Half year consolidated results' report for SkinBioTherapeutics plc for the six months ending 31 December 2022. It includes detailed financial statements, operational reviews, management commentary, and financial highlights. It is not an announcement of a report (RPA) because it contains the full substantive content of the interim results. Therefore, it is classified as an Interim / Quarterly Report. H1 2023
2023-03-28 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half year consolidated results' report for SkinBioTherapeutics plc for the six months ending 31 December 2022. It contains detailed financial statements, operational reviews, and management commentary. It is not a mere announcement of a report (RPA) because it contains the substantive financial data and analysis itself. Therefore, it is classified as an Interim/Quarterly Report. H1 2023
2023-03-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.